Monitoring Agency Report for the quarter and year ended 31 March 2026
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences Limited has filed its Q4 FY2026 monitoring agency report for the IPO that opened in December 2024. The IPO raised Rs 30,426.20 million (fresh issue of Rs 9,500 million plus offer for sale of Rs 20,926.20 million). Of the Rs 9,500 million fresh issue proceeds, Rs 7,200 million for debt repayment and Rs 1,898.84 million for general corporate purposes have been fully utilized. Rs 345.88 million has been spent on issue expenses, with Rs 55.28 million remaining parked in fixed deposits and public offer accounts. No utilization occurred during Q4 FY2026 as the remaining funds await final settlement. CRISIL Ratings Limited, the appointed monitoring agency, has confirmed no deviations from the disclosed objects of the issue.
The report shows proper utilization of IPO proceeds as per the offer document with no material deviations. The remaining Rs 55.28 million in unutilized funds is parked in fixed deposits earning 5.45% interest. This is a routine compliance filing indicating the IPO fund deployment is on track.